StockData
DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Dyne Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$15.23+0.98 (+6.88%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 29, 2026After market close–$-1.08–
Q1 FY2026
Ended Mar 31, 2026
May 11, 2026Before market open–$-0.73–
Q4 FY2025
Ended Dec 31, 2025
Mar 2, 2026Before market open–$-0.76–
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025After market close–$-0.76–
Q2 FY2025
Ended Jun 30, 2025
Jul 28, 2025After market close–$-0.97–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open–––
Q4 FY2024
Ended Dec 31, 2024
Feb 27, 2025Before market open–$-0.88–
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024Before market open–$-0.96–
Q2 FY2024
Ended Jun 30, 2024
Aug 12, 2024After market close–$-0.70–
Q1 FY2024
Ended Mar 31, 2024
May 2, 2024After market close–$-0.81–
Q4 FY2023
Ended Dec 31, 2023
Mar 5, 2024Before market open–$-1.09–

Press releases

Announcements Dyne Therapeutics filed with the SEC